Structural interactions between inhibitor and substrate docking sites give insight into mechanisms of human PS1 complexes

Structure. 2014 Jan 7;22(1):125-35. doi: 10.1016/j.str.2013.09.018. Epub 2013 Nov 7.

Abstract

Presenilin-mediated endoproteolysis of transmembrane proteins plays a key role in physiological signaling and in the pathogenesis of Alzheimer disease and some cancers. Numerous inhibitors have been found via library screens, but their structural mechanisms remain unknown. We used several biophysical techniques to investigate the structure of human presenilin complexes and the effects of peptidomimetic γ-secretase inhibitors. The complexes are bilobed. The head contains nicastrin ectodomain. The membrane-embedded base has a central channel and a lateral cleft, which may represent the initial substrate docking site. Inhibitor binding induces widespread structural changes, including rotation of the head and closure of the lateral cleft. These changes block substrate access to the catalytic pocket and inhibit the enzyme. Intriguingly, peptide substrate docking has reciprocal effects on the inhibitor binding site. Similar reciprocal shifts may underlie the mechanisms of other inhibitors and of the "lateral gate" through which substrates access to the catalytic site.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allosteric Regulation
  • Amyloid Precursor Protein Secretases / chemistry
  • Benzodiazepinones / chemistry*
  • Catalytic Domain
  • Enzyme Inhibitors / chemistry*
  • HEK293 Cells
  • Humans
  • Ligands
  • Membrane Glycoproteins / chemistry
  • Molecular Docking Simulation
  • Peptidomimetics / chemistry*
  • Presenilin-1 / antagonists & inhibitors
  • Presenilin-1 / chemistry*
  • Presenilin-1 / genetics
  • Protein Structure, Tertiary
  • Proteolysis
  • Recombinant Fusion Proteins / chemistry*
  • Recombinant Fusion Proteins / genetics
  • Structure-Activity Relationship

Substances

  • 2-(((3,5-difluorophenyl)acetyl)amino)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)propanamide
  • Benzodiazepinones
  • Enzyme Inhibitors
  • Ligands
  • Membrane Glycoproteins
  • PSEN1 protein, human
  • Peptidomimetics
  • Presenilin-1
  • Recombinant Fusion Proteins
  • nicastrin protein
  • Amyloid Precursor Protein Secretases